Ambitious European biotech firms still look to the US when they need large sums of venture capital, according to EU officials, who fear home-grown talent is crossing the Atlantic.
Not only is it easier for high-growth start-ups to access funding in the
US – enticing young research-based companies to abandon Europe – but
Europe's own venture capital industry continues to lose the expertise of
talented fund managers.
To read the full, original article click on this link: Biotech start-ups turn to US for finance | EurActiv
Author: EurActiv.com
